Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onametostat - Johnson & Johnson

Next Previous
Drug Profile

Onametostat - Johnson & Johnson

Alternative Names: JNJ-64619178; JNJ-9178

Latest Information Update: 01 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Class Antineoplastics; Cyclopentanes; Pyrimidines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action PRMT5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 25 Sep 2025 Phase I trial is still ongoing for Myelodysplastic syndromes (Late-stage disease), Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater), and Solid tumours (Late-stage disease) in Canada, Spain, Germany, Israel and in USA (NCT03573310)
  • 25 Sep 2025 Johnson & Johnson completes a phase I trial for Myelodysplastic syndromes (Late-stage disease), Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater), and Solid tumours (Late-stage disease) in Canada, Spain, Germany, Israel and in USA (NCT03573310)
  • 09 Apr 2024 Pharmacodynamics data from a preclinical study in pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top